Clay Siegall founded Seattle Genetics in 1998 with the goal in mind to help create targeted treatments for cancer patients. When he started his company, the main treatment was chemotherapy. The biggest issue with chemotherapy was that it did not discriminate between healthy cells and cancer cells. Siegall felt that therapies should be more targeted.
Siegall is a trained scientist and started Seattle Genetics with a basic foundation of research, scientific innovation, and drug development. Through his leadership, they have become an industry leader in antibody drug conjugates and the patent holder for the ADC drug Adcetris. This cancer treatment therapy targets the affected cells. With their partnership with Takeda pharmaceuticals, AdCetris is the leading ADC brand in 65 countries. Through their partnerships with companies like GlaxoSmithKline and Pfizer, they have developed almost 20 ADCs to date and generated 350 million in licenses. ADC technology has helped to make more targeted cancer treatment a reality.
Clay Siegall earned his PhD in genetics from George Washington University. Currently, he is the author of 70 publications and holds 15 patents. His experience from the Bristol-Myers Squibb Pharmaceutical Research Institute, National Institute of Health, and National Cancer Institutes has helped him steer Seattle Genetics in the direction it is today. He serves on several boards, including Ultragenyx Pharmaceuticals, Alder BioPharmaceuticals, and Washington Roundtable. He has earned the 2012 Pacific Northwest Ernst & Young Entrepreneur of the Year and the 2013 University of Maryland Alumnus of the Year award for Computer, Math, and Natural Sciences.